← Back to Clinical Trials
Recruiting Phase 1 NCT06702488

Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics

Trial Parameters

Condition Mental Disorder
Sponsor Fayoum University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 58
Sex ALL
Min Age 60 Years
Max Age 80 Years
Start Date 2024-11-21
Completion 2025-04-30
Interventions
dexmedetomidine

Brief Summary

Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology. Magnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy. The aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.

Eligibility Criteria

Inclusion Criteria: * ASA physical status I, II and ⅠⅠⅠ * patients undergoing open abdominal surgery under general anesthesia Exclusion Criteria: * Elderly patients with preoperative MoCA Score below 26. * Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate. * BMI \> 35 kg m-2

Related Trials